Amarantus BioScience Holdings, Inc. Q1-2014: The Maturation of Amarantus - FOX 18 Quad Cities News and Weather

Amarantus BioScience Holdings, Inc. Q1-2014: The Maturation of Amarantus

Posted: Updated:

Amarantus Bioscience Holdings, Inc.
(OTCQB:AMBS) published a new blog post on The Chairman’s Blog,
written by the company’s CEO, Gerald Commissiong.
TheChairmansBlog.com is an exclusive online media publication that
provides key executive officers and key opinion leaders a unique
platform to share insights about company and industry trends.

Amarantus
CEO, Gerald Commissiong writes about the implications of being a
small company in the biotech industry. He highlights the recent
progress Amarantus has made, with additions to the management team
and the expansion of the Company’s pipeline. Mr. Commissiong
writes, “For Amarantus, we have taken the view that building a
world-class biotechnology company in the absence of product revenue
(for the time being) requires a number of key elements in order to
truly thrive.” Read about those key elements in his blog post on
TheChairmansBlog.com
(http://www.thechairmansblog.com/amarantus-bioscience/gerald-commissiong/q1-2014-maturation-amarantus/)

About Amarantus

Amarantus is a
biotechnology company developing treatments and diagnostics for
diseases associated with neurodegeneration and protein
misfolding-related apoptosis. The Company has licensed Eltoprazine a
phase 2b ready indication for Parkinson’s Levodopa induced
dyskinesia. The Company has an exclusive worldwide license to the
Lymphocyte Proliferation test (“LymPro Test®”) for
Alzheimer’s disease and owns the intellectual property rights to a
therapeutic protein known as Mesencephalic-Astrocyte-derived
Neurotrophic Factor (“MANF”) and is developing MANF-based
products as treatments for brain disorders. Amarantus is a Founding
Member of the Coalition for Concussion Treatment (#C4CT), a movement
initiated in collaboration with Brewer Sports International seeking
to raise awareness of new treatments in development for concussions
and nervous-system disorders. The Company also owns intellectual
property for the diagnosis of Parkinson’s disease (“NuroPro”)
and the discovery of neurotrophic factors (“PhenoGuard”).
For further information please visit www.Amarantus.com,
or connect with the Company on Facebook,
LinkedIn,
Twitter
and Google+.

About TheChairmansBlog.com

TheChairmansBlog.com is
an exclusive, online media publication where publically and
privatively held firms alike share insights about their companies and
industries. TheChairmansBlog.com enables upper tier management to
discuss issues that are of importance to their stakeholders,
shareholders, and interested parties in an informal environment. In
addition to management`s insightful blog posts, TheChairmansBlog.com
staff and aggregate partners contribute articles on finance,
technology, health, and energy while providing updated market trends,
news, and information.

ReleaseID: 412242

Powered by WorldNow